MarketBeat on MSN1h
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
PipelineReview.com4h
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...
Scripps Research gives old anti-malaria drug better staying power
Working with a contract drug manufacturing and testing firm in the United Kingdom, 25 to 30 healthy volunteers are now ...
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
HIV stigma tied to moral judgments, complicating destigmatization efforts
Persistence of stigma toward people living with HIV has puzzled scientists looking at the numerous destigmatization campaigns ...
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...